A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248
This study is recruiting at 11 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration Resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- ORIC Pharmaceuticals
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- SSAK Partners, LLC · Coral Springs, FL
Indiana · 1
- First Urology PSC · Jeffersonville, IN
Michigan · 1
- Cancer And Hematology Centers Of Western Michigan · Holland, MI
North Carolina · 1
- Urology Specialists of the Carolinas - University Place · Charlotte, NC
Ohio · 1
- Gabrail Cancer Center Research · Canton, OH
South Carolina · 1
- Carolina Urologic Research Center · Myrtle Beach, SC
Tennessee · 1
- Urology Associates · Nashville, TN
Texas · 3
- Urology Clinics Of North Texas · Dallas, TX
- Urology Partners of North Texas (UPNT) · Fort Worth, TX
- Houston Metro Urology (HMU) · Houston, TX
Utah · 1
- Summit Urology · Murray, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.